tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Uveitis D014605 14 associated lipids
Urticaria D014581 13 associated lipids
Urination Disorders D014555 9 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Uremia D014511 33 associated lipids
Ulcer D014456 16 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Trypanosomiasis D014352 5 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
Trichomonas Infections D014245 3 associated lipids
Tremor D014202 15 associated lipids
Translocation, Genetic D014178 20 associated lipids
Toxocariasis D014120 3 associated lipids
Tongue Diseases D014060 2 associated lipids
Tinea Capitis D014006 1 associated lipids
Tinea D014005 5 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Thyroid Diseases D013959 8 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Thrombosis D013927 49 associated lipids
Thrombophlebitis D013924 6 associated lipids
Thrombocytopenia D013921 15 associated lipids
Thinness D013851 11 associated lipids
Testicular Diseases D013733 15 associated lipids
Telangiectasis D013684 2 associated lipids
Tachycardia D013610 7 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Stomatitis D013280 14 associated lipids
Stomach Ulcer D013276 75 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Skin Neoplasms D012878 12 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Sinusitis D012852 9 associated lipids
Shock, Septic D012772 11 associated lipids
Shock D012769 11 associated lipids
Seizures D012640 87 associated lipids
Dermatitis, Seborrheic D012628 10 associated lipids
Sclerosis D012598 5 associated lipids
Scalp Dermatoses D012536 11 associated lipids
Osteosarcoma D012516 50 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
Sarcoidosis D012507 13 associated lipids
Rupture D012421 2 associated lipids
Rotavirus Infections D012400 1 associated lipids
Rosacea D012393 13 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Retinoblastoma D012175 12 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Moon BJ et al. Effect of chronic rhinosinusitis on liver transplant patients. 2009 Sep-Oct Am J Rhinol Allergy pmid:19807981
Shin JH et al. The effect of topical FK506 (tacrolimus) in a mouse model of allergic rhinitis. 2012 Mar-Apr Am J Rhinol Allergy pmid:22487280
Vearrier D et al. Mutism and persistent dysarthria due to tacrolimus-based immunosuppression following allogeneic liver transplantation. 2011 Am J Ther pmid:20535006
Yang A and Wang B Sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids: focus on acute rejection, patient and graft survival. Am J Ther pmid:23921809
Pariser D Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption. 2009 May-Jun Am J Ther pmid:19262357
Sathyan S et al. Prevention of recurrent episodes of rhabdomyolysis with tacrolimus in a transplant recipient with myopathy. Am J Ther pmid:23429166
Liu JY et al. Tacrolimus Versus Cyclosporine as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation. Am J Ther pmid:25299636
Haroon N et al. Tacrolimus Toxicity With Minimal Clinical Manifestations: A Case Report and Literature Review. Am J Ther pmid:25730156
Nunokawa T et al. Late-onset scleroderma renal crisis induced by tacrolimus and prednisolone: a case report. Am J Ther pmid:22836123
Liu JY et al. Sirolimus Versus Tacrolimus as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation. Am J Ther pmid:25569597
Cohen SM Current immunosuppression in liver transplantation. 2002 Mar-Apr Am J Ther pmid:11897926
Yousuf Bhat Z et al. Colchicine-Induced Myopathy in a Tacrolimus-Treated Renal Transplant Recipient: Case Report and Literature Review. Am J Ther pmid:24732905
Azizian M et al. Augmentation of ischemia/reperfusion injury to endothelial cells by cyclosporin A. 2004 Am Surg pmid:15156953
Henderson CN et al. Continuous Abdominal Irrigation for Treatment of Tertiary Peritonitis in the Immunosuppressed Patient after Solid Organ Transplant: A Novel Approach. 2017 Am Surg pmid:28424115
Rojas-García P et al. Breast fibroadenomas associated with immunosuppressive drugs. 2010 Am Surg pmid:21418766
Kodama M et al. FK506 therapy of experimental autoimmune myocarditis after onset of the disease. 1993 Am. Heart J. pmid:7504393
Chieffo A et al. Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents. 2009 Am. J. Cardiol. pmid:19962471
Chang RK et al. Marked left ventricular hypertrophy in children on tacrolimus (FK506) after orthotopic liver transplantation. 1998 Am. J. Cardiol. pmid:9604971
Klauss V et al. Cyclosporine versus tacrolimus (FK 506) for prevention of cardiac allograft vasculopathy. 2000 Am. J. Cardiol. pmid:10955391
Herzberg GZ et al. Usefulness of tacrolimus versus cyclosporine after pediatric heart transplantation. 1998 Am. J. Cardiol. pmid:9723652
Hisamura F et al. Synergistic effect of green tea polyphenols on their protection against FK506-induced cytotoxicity in renal cells. 2008 Am. J. Chin. Med. pmid:18543393
Chung SY et al. Ginkgo biloba leaf extract (EGb761) combined with neuroprotective agents reduces the infarct volumes of gerbil ischemic brain. 2006 Am. J. Chin. Med. pmid:17080546
Stickle DF et al. Effects of sterilizing gamma irradiation on bloodspot newborn screening tests and whole blood cyclosporine and tacrolimus measurements. 2003 Am. J. Clin. Pathol. pmid:12580001
Wang E et al. Pseudo-Pelger-Huët anomaly induced by medications: a clinicopathologic study in comparison with myelodysplastic syndrome-related pseudo-Pelger-Huët anomaly. 2011 Am. J. Clin. Pathol. pmid:21228370
Burke MT et al. Expression of Bcl-xL and Mcl-1 in the nonmelanoma skin cancers of renal transplant recipients. 2015 Am. J. Clin. Pathol. pmid:25780003
Lower DR et al. Comparison of CEDIA FK506 assay with HPLC/MS/MS in a large cohort of pediatric patients. 2013 Am. J. Clin. Pathol. pmid:23690122
Rudi J et al. Prevalence of serum antibodies to Helicobacter pylori and to CagA protein in liver transplant recipients. 1997 Am. J. Gastroenterol. pmid:9317070
Van Thiel DH et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. 1995 Am. J. Gastroenterol. pmid:7532912
Baumgart DC et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. 2006 Am. J. Gastroenterol. pmid:16573777
Sandborn WJ Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. 1997 Am. J. Gastroenterol. pmid:9149205
Van Thiel DH et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. 1995 Am. J. Gastroenterol. pmid:7537444
Fellermann K et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). 1998 Am. J. Gastroenterol. pmid:9772045
Nara M et al. Effect of oral itraconazole on the pharmacokinetics of tacrolimus in a hematopoietic stem cell transplant recipient with CYP3A5*3/*3. 2010 Am. J. Hematol. pmid:20568249
Lekakis LJ et al. BK virus nephropathy after allogeneic stem cell transplantation: a case report and literature review. 2009 Am. J. Hematol. pmid:19208419
Hammerstrom AE et al. Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. 2013 Am. J. Hematol. pmid:23460378
Abdel-Azim H et al. Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. 2015 Am. J. Hematol. pmid:26242764
Uehara T et al. Successful control of Epstein-Barr virus (EBV)-infected cells by allogeneic nonmyeloablative stem cell transplantation in a patient with the lethal form of chronic active EBV infection. 2004 Am. J. Hematol. pmid:15282671
Nakamae H et al. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. 2006 Am. J. Hematol. pmid:16755559
Bolaños-Meade J et al. Lymphocytic pneumonitis as the manifestation of acute graft-versus-host disease of the lung. 2005 Am. J. Hematol. pmid:15929116
Ninan MJ and Datta YH Post-transplant lymphoproliferative disorder presenting as multiple myeloma. 2010 Am. J. Hematol. pmid:20578201
Mach-Pascual S et al. Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy. 1996 Am. J. Hematol. pmid:8701950
Uehara T et al. A successful second unrelated BMT (UBMT) from a different unrelated donor to treat ALL that relapsed after the initial UBMT. 2002 Am. J. Hematol. pmid:12221672
Cohen DL et al. Pulse wave analysis to assess vascular compliance changes in stable renal transplant recipients. 2004 Am. J. Hypertens. pmid:15001192
Zhang W and Victor RG Calcineurin inhibitors cause renal afferent activation in rats: a novel mechanism of cyclosporine-induced hypertension. 2000 Am. J. Hypertens. pmid:10981550
Taler SJ et al. Loss of nocturnal blood pressure fall after liver transplantation during immunosuppressive therapy. 1995 Am. J. Hypertens. pmid:7544983
de Mattos AM et al. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. 2000 Am. J. Kidney Dis. pmid:10676738
Kooman JP et al. A comparison between office and ambulatory blood pressure measurements in renal transplant patients with chronic transplant nephropathy. 2001 Am. J. Kidney Dis. pmid:11382685
Rostaing L et al. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. 2016 Am. J. Kidney Dis. pmid:26717860
Paoletti E et al. ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: a randomized clinical trial. 2007 Am. J. Kidney Dis. pmid:17591533
Reese PP et al. Automated Reminders and Physician Notification to Promote Immunosuppression Adherence Among Kidney Transplant Recipients: A Randomized Trial. 2017 Am. J. Kidney Dis. pmid:27940063